These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 1689919)

  • 21. HIV-1 matrix protein p17: a candidate antigen for therapeutic vaccines against AIDS.
    Fiorentini S; Giagulli C; Caccuri F; Magiera AK; Caruso A
    Pharmacol Ther; 2010 Dec; 128(3):433-44. PubMed ID: 20816696
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of mucosal immunity in development of an acquired immunodeficiency syndrome (AIDS) vaccine: workshop summary.
    Muul LM; Glass MJ; Wescott SL; Burkhardt AL; Koff WC; Strober WG
    Reg Immunol; 1989; 2(3):188-92. PubMed ID: 2701579
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Repertoire of epitopes of human immunodeficiency virus proteins and the search for vaccines and diagnostic kits].
    Kharchenko EP; Klimenko AP
    Dokl Akad Nauk SSSR; 1992; 322(1):189-92. PubMed ID: 1380907
    [No Abstract]   [Full Text] [Related]  

  • 24. [HIV/AIDS vaccines: heading for new vaccine approaches?].
    Girard MP
    Bull Soc Pathol Exot; 2008 Jun; 101(3):220-6. PubMed ID: 18681215
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A recombinant live attenuated measles vaccine vector primes effective HLA-A0201-restricted cytotoxic T lymphocytes and broadly neutralizing antibodies against HIV-1 conserved epitopes.
    Lorin C; Delebecque F; Labrousse V; Da Silva L; Lemonnier F; Brahic M; Tangy F
    Vaccine; 2005 Aug; 23(36):4463-72. PubMed ID: 15993518
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines.
    VanCott TC; Bethke FR; Burke DS; Redfield RR; Birx DL
    J Immunol; 1995 Oct; 155(8):4100-10. PubMed ID: 7561123
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of antibody parameters as potential correlates of protection or enhancement by experimental vaccines to equine infectious anemia virus.
    Hammond SA; Raabe ML; Issel CJ; Montelaro RC
    Virology; 1999 Sep; 262(2):416-30. PubMed ID: 10502520
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Robust HIV-specific immune responses were induced by DNA vaccine prime followed by attenuated recombinant vaccinia virus (LC16m8 strain) boost.
    Shinoda K; Xin KQ; Kojima Y; Saha S; Okuda K; Okuda K
    Clin Immunol; 2006 Apr; 119(1):32-7. PubMed ID: 16458074
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Natural immunity to HIV and its possible relationship to vaccine strategies.
    Bolognesi DP
    Microbiol Sci; 1988 Aug; 5(8):236-41. PubMed ID: 2484203
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term memory B-cell responses in recipients of candidate human immunodeficiency virus type 1 vaccines.
    Evans TG; Frey S; Israel H; Chiu J; El-Habib R; Gilbert P; Gaitan A; Montefiori DC;
    Vaccine; 2004 Jun; 22(20):2626-30. PubMed ID: 15193388
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current status and strategies for vaccines against diseases induced by human T-cell lymphotropic retroviruses (HTLV-I, -II, -III).
    Fischinger PJ; Robey WG; Koprowski H; Gallo RC; Bolognesi DP
    Cancer Res; 1985 Sep; 45(9 Suppl):4694s-4699s. PubMed ID: 2410115
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The kinetics of specific immune responses in rhesus monkeys inoculated with live recombinant BCG expressing SIV Gag, Pol, Env, and Nef proteins.
    Leung NJ; Aldovini A; Young R; Jarvis MA; Smith JM; Meyer D; Anderson DE; Carlos MP; Gardner MB; Torres JV
    Virology; 2000 Mar; 268(1):94-103. PubMed ID: 10683331
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mucosally-administered human-simian immunodeficiency virus DNA and fowlpoxvirus-based recombinant vaccines reduce acute phase viral replication in macaques following vaginal challenge with CCR5-tropic SHIVSF162P3.
    Kent SJ; Dale CJ; Ranasinghe C; Stratov I; De Rose R; Chea S; Montefiori DC; Thomson S; Ramshaw IA; Coupar BE; Boyle DB; Law M; Wilson KM; Ramsay AJ
    Vaccine; 2005 Oct; 23(42):5009-21. PubMed ID: 15985317
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Immunization against the human immunodeficiency virus in Zaire].
    Zagury D; Salaün JJ; Bernard J; Dechazal L; Goussard B; Lurhuma Z
    Med Trop (Mars); 1988; 48(4):417-23. PubMed ID: 3221792
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The prospects for and pathways toward a vaccine for AIDS.
    Francis DP; Petricciani JC
    N Engl J Med; 1985 Dec; 313(25):1586-90. PubMed ID: 2999596
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neutralizing antibodies and antigens in AIDS.
    Norley SG; Kurth R
    Infection; 1991; 19 Suppl 2():S83-8. PubMed ID: 1707855
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Strategies for developing vaccines against acquired immunodeficiency syndrome.
    Zhou EM; Kennedy RC
    Biochim Biophys Acta; 1989 Dec; 989(3):301-13. PubMed ID: 2695171
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Acquired immunologic deficiency syndrome (AIDS). I. Biologic principles].
    Negele J; Kaschka WP
    Fortschr Neurol Psychiatr; 1987 Jun; 55(6):175-88. PubMed ID: 3475243
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Toward a vaccine for AIDS: the emergence of immunobiology-based vaccine development.
    Cease KB; Berzofsky JA
    Annu Rev Immunol; 1994; 12():923-89. PubMed ID: 7516670
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Trends in research in developing new type of vaccines--aiming at efficacy and safety. Present status of the development of AIDS vaccine].
    Kitamura T
    Nihon Rinsho; 1987 Oct; 45(10):2444-7. PubMed ID: 3448276
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.